

Causal relevance of obesity on the leading causes of death in women and men: A Mendelian randomization study

Short title: Relevance of obesity to the leading causes of death in women and men

Jenny C Censin, MD^{1,2}

Jonas Bovijn, MD^{1,2}

Teresa Ferreira, PhD¹

Sara L Pulit, PhD^{1,3,4}

Reedik Mägi, PhD⁵

Anubha Mahajan, PhD^{2,6}

Michael V Holmes, MD PhD^{7-9*}

Cecilia M Lindgren, PhD^{1,2,4*}

* These authors contributed equally

Affiliations:

1. Big Data Institute at the Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK
2. Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3. Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
4. Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA
5. Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia

6. Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
7. NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
8. Medical Research Council Population Health Research Unit at the University of Oxford, Nuffield Department of Population Health, University of Oxford, Oxford, UK
9. Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, Big Data Institute Building, Roosevelt Drive, University of Oxford, Oxford, UK

Corresponding author:

Name: Prof. Cecilia M Lindgren

E-mail: lindgrenpa@bdi.ox.ac.uk

Abstract

Background

Obesity traits are causally implicated with risk of cardiometabolic diseases. It remains unclear whether there are similar causal effects of obesity traits on other non-communicable diseases. Also, it is largely unexplored whether there are any sex-specific differences in the causal effects of obesity traits on cardiometabolic diseases and other leading causes of death. We therefore tested associations of sex-specific genetic risk scores (GRSs) for body mass index (BMI), waist-hip-ratio (WHR), and WHR adjusted for BMI (WHRadjBMI) with leading causes of mortality, using a Mendelian randomization (MR) framework.

Methods and Findings

We constructed sex-specific GRSs for BMI, WHR, and WHRadjBMI, including 565, 324, and 338 genetic variants, respectively. These GRSs were then used as instrumental variables to assess associations between the obesity traits and leading causes of mortality using an MR design in up to 422,414 participants from the UK Biobank. We also investigated associations with potential mediators and risk factors, including smoking, glycemic and blood pressure traits. Sex-differences were subsequently assessed by Cochran's Q-test (P_{het}).

Up to 227,717 women and 194,697 men with mean (standard deviation) age 56.6 (7.9) and 57.0 (8.1) years, body mass index 27.0 (5.1) and 27.9 (4.2) kg/m^2 and waist-hip-ratio 0.82 (0.07) and 0.94 (0.07), respectively, were included. Mendelian randomization analysis showed that obesity causes coronary artery disease, stroke (particularly ischemic), chronic obstructive pulmonary disease, lung cancer, type 2 and 1 diabetes mellitus, non-alcoholic fatty liver disease, chronic liver disease, and acute and chronic renal failure. A 1 standard deviation higher body mass index led to higher risk of type 2 diabetes in women (OR 3.81; 95% CI 3.42-4.25, $P=8.9 \times 10^{-130}$) than in men (OR 2.78; 95% CI 2.57-3.02, $P=1.0 \times 10^{-133}$, $P_{het}=5.1 \times 10^{-6}$). Waist-hip-ratio led to a higher risk of chronic obstructive pulmonary disease ($P_{het}=5.5 \times 10^{-6}$) and higher risk of chronic renal failure ($P_{het}=1.3 \times 10^{-4}$) in men than women.

A limitation of MR studies is potential bias if the genetic variants are directly associated with confounders (pleiotropy), but sensitivity analyses such as MR-Egger supported the main findings. Our study was also limited to people of European descent and results may differ in people of other ancestries.

Conclusions

Obesity traits have an etiological role in the majority of the leading global causes of death. Sex differences exist in the effects of obesity traits on risk of type 2 diabetes, chronic obstructive pulmonary disease, and renal failure, which may have implications on public health.

Abbreviations

BMI, Body mass index; CAD: coronary artery disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; FG, fasting glucose; FI, fasting insulin; GIANT, Genetic Investigation of ANthropometric Traits; GRS, genetic risk score; GWAS, genome-wide association study; MAGIC, the Meta-Analyses of Glucose and Insulin-related traits Consortium; MR, Mendelian randomization; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; T1D, type 1 diabetes; T2D, type 2 diabetes; SBP, systolic blood pressure; SD, standard deviation; SNP, single nucleotide polymorphism; WHO, the World Health Organization; WHR, waist-hip-ratio; WHRadjBMI, waist-hip-ratio adjusted for body mass index.

Introduction

It is increasingly evident that obesity negatively impacts human health and the prevalence of obesity is increasing world-wide (1). Obesity and central fat distribution, commonly measured by body mass index (BMI; obesity usually defined as BMI >30 kg/m²) and waist-hip-ratio (WHR), respectively, have been linked to cardiometabolic diseases and death in observational studies (2–5). However, conventional observational studies can be affected by bias, confounding, and reverse causation, which might lead to erroneous findings. Mendelian randomization (MR) offers an approach to circumvent these issues by using single nucleotide polymorphisms (SNPs) that reliably associate with an exposure as an instrument to test the causal relationship between an exposure and outcome (6). Owing to the nature of genotypes and therefore genetic associations, MR estimates should be less affected by confounding and reverse causation (S1 Supporting Information) (6). Previous studies have found causal relationships between for example higher BMI and WHR adjusted for BMI (WHRadjBMI) and type 2 diabetes (T2D) and coronary artery disease (CAD), mostly using a limited number of previously known obesity-associated SNPs (7–12). However, previous studies have not thoroughly investigated causal sex-specific relationships, nor have they comprehensively investigated the role that obesity traits play in the leading causes of death beyond these cardiometabolic diseases.

Obesity traits differ between women and men—for example, regional obesity prevalence rates often vary between the sexes (13,14), women have higher SNP-based heritability for WHR (15), and >90% of WHRadjBMI-associated SNPs that show evidence of sexual dimorphism have larger effect sizes in women than men (15). Observational studies have indicated that waist-related traits might be more strongly associated with cardiometabolic outcomes in women, although previous studies are inconclusive (16–20). Only a few studies have investigated sex differences in the effect of genetic risk for obesity-related traits on disease risk (7,10,12). These studies have mostly been restricted to waist-related traits and T2D and CAD, using a limited number of analyses and/or SNPs, but without finding evidence of differences in disease risk between men and women (7,10,12).

A sex difference in the effect of obesity traits on major causes of death could signify that disease burden arising from obesity may be differential in women and men, allowing prioritizing of public

health resources and potentially, sex-specific preventative strategies. We therefore investigated the extent to which obesity traits causally impact the risk of the major global causes of death, and whether relationships with disease are differential between women and men, exploiting recent advances in discovery of obesity-associated SNPs (15).

Methods

Data sources and study participants

The UK Biobank is a prospective UK-based cohort study, with 488,377 genotyped individuals aged 40-69 when recruited (21). UK Biobank has a Research Tissue Bank approval (Research Ethics Committee reference 16/NW/0274, this study's application ID 11867), and all participants gave informed consent.

In the present study, genotype data for up to 422,414 individuals were included, after general genotype and sample quality control procedures, and exclusion of people of non-European ancestry (S1 Supporting Information). Participant characteristics are in Table 1.

Table 1. Characteristics of UK Biobank Participants included in the study.

Characteristic	Men	Women
Individuals, N (%)	194,697 (46.1)	227,717 (53.9)
British, N (%) ^a	173,947 (89.3)	201,278 (88.4)
Age, mean (SD), years	57.0 (8.1)	56.6 (7.9)
UK BiLEVE array, N (%) ^b	23,187 (11.9)	22,755 (10.0)
Body mass index, mean (SD), kg/m ²	27.9 (4.2)	27.0 (5.1)
Waist circumference, mean (SD), cm	97.1 (11.3)	84.5 (12.5)
Hip circumference, mean (SD), cm	103.5 (7.6)	103.3 (10.3)
Waist-hip-ratio, mean (SD)	0.94 (0.07)	0.82 (0.07)
Systolic blood pressure, mean (SD), mmHg	144.8 (19.4)	138.0 (21.2)
Diastolic blood pressure, mean (SD), mmHg	86.6 (11.0)	82.3 (11.1)
Type 2 diabetes cases, N (%)	11,768 (6.0)	6,533 (2.9)
Coronary artery disease cases, N (%)	24,430 (12.5)	11,565 (5.1)
Breast cancer cases, N (%)	-	14,294 (6.3)
Chronic liver disease cases, N (%)	822 (0.4)	542 (0.2)
Colorectal cancer cases, N (%)	3,145 (1.6)	2,368 (1.0)
COPD cases, N (%)	7,890 (4.1)	6,789 (3.0)
Dementia cases, N (%)	580 (0.3)	448 (0.2)
Infertility cases, N (%)	85 (0.0)	1,588 (0.7)
Lung cancer cases, N (%)	1,473 (0.8)	1,244 (0.5)

Characteristic	Men	Women
NAFLD cases, N (%)	912 (0.5)	778 (0.3)
Renal failure cases, N (%)	5,704 (2.9)	3,902 (1.7)
Renal failure, acute, cases, N (%)	3,045 (1.6)	1,643 (0.7)
Renal failure, chronic, cases, N (%)	2,581 (1.3)	2,019 (0.9)
Stroke cases, N (%)	6,329 (3.3)	4,437 (1.9)
Stroke, hemorrhagic, cases, N (%)	929 (0.5)	972 (0.4)
Stroke, ischemic, cases, N (%)	2,167 (1.1)	1,177 (0.5)
Type 1 diabetes cases, N (%)	824 (0.4)	675 (0.3)

COPD, chronic obstructive pulmonary disease; NAFLD, non-alcoholic fatty liver disease; SD, standard deviation.

^aParticipants were denoted as “British” if they were in the British ancestry subset as defined by the UK Biobank (21) (based on self-report of British ancestry and similar ancestry according to principal components analysis)

^bUK BiLEVE array is the number of participants genotyped on that array as opposed to the UK Biobank Axiom array

Instruments

We evaluated several approaches to construct sex-specific genetic risk scores (GRSs) for BMI, WHR, and WHRadjBMI (S1 Supporting Information, Fig A-B in S1 Supporting Information). The approach with the highest ranges of trait variance explained and F-statistics for the relevant obesity trait, and with no demonstrable heterogeneity between men and women, was selected as the main model. In this model, GRSs were constructed by including the primary (“index”) genome-wide significant ($P < 5 \times 10^{-9}$) SNPs in the men, women, or combined-sexes analyses in the largest genome-wide association study (GWAS) available with sex-specific European summary statistics, a meta-analysis of the Genetic Investigation of ANthropometric Traits (GIANT) (22,23) and the UK Biobank (Fig 1, S1 Supporting Information) (15). Primary SNPs were identified in the original GWAS (15) by proximal and joint conditional analysis using GCTA in associated loci. Associated loci included all SNPs (associated with the GWAS obesity trait $P < 0.05$) ± 5 Mb around a top SNP ($P < 5 \times 10^{-9}$) and that were in linkage disequilibrium (LD; $r^2 > 0.05$) with the top SNP; overlapping loci were merged (15). We then kept the SNP with the lowest combined-sexes P-value within each 1 Mb sliding window to limit correlation between SNPs discovered in different sex-strata in each obesity trait. We excluded non-biallelic SNPs (N=2), SNPs that failed quality control (N=2), and one SNP per pair with long-distance linkage disequilibrium ($r^2 > 0.05$, N=2) (S1 Supporting Information). For the combined-sexes analyses, SNPs were weighted using estimates from the combined-sexes European meta-analyzed GWASs. For the men- and women-only analyses, SNPs were weighted by their sex-specific European estimates. All

SNPs were orientated so that the effect allele corresponded to a higher level of the investigated obesity trait.




Fig 1. SNP- and weight selection flowchart with number of SNPs for each obesity trait.

SNPs were selected by including the primary ("index") variants for each associated (with SNPs $P < 5 \times 10^{-9}$) locus (assessed for a minimum of ± 5 Mb around the top SNP and including all SNPs in linkage disequilibrium $R^2 > 0.05$ and $P < 0.05$, and with primary variants as determined through joint and conditional testing using GCTA in the original study (15)), in any of the men, women, and combined-sexes genome-wide association studies for each obesity trait (15). To further ascertain independence for SNPs selected from different sex-stratified genome-wide association studies and to have the same set of SNPs for all sex-strata, only the SNP with the lowest combined-sexes P-value within each 1 Mb-window was kept. SNPs that were non-biallelic ($N=2$) or that failed quality control ($N=2$) were removed, as was one SNP in each pair with long-distance linkage disequilibrium ($N=2$, using a linkage disequilibrium threshold of $r^2 < 0.05$ and removing the SNP with the highest combined-sexes P-value). All SNPs were then weighted by their sex-specific Europeans estimates for the men- and women analyses, and by the combined-sexes European estimates for the combined-sexes analyses, using estimates from the original genome-wide association study (15). BMI, body mass index; SNP, single nucleotide polymorphism; WHR, waist-hip-ratio; WHRadjBMI, waist-hip-ratio adjusted for body mass index.

Outcomes

We investigated associations between three obesity traits (BMI, WHR, and WHRadjBMI) with all non-communicable diseases on the World Health Organization's (WHO) list of leading mortality

causes world-wide and in high-income countries (24); CAD, stroke (including ischemic, hemorrhagic, and of any cause), chronic obstructive pulmonary disease (COPD), dementia, lung cancer, T2D and type 1 diabetes (T1D), colorectal cancer, renal failure (including acute, chronic and of any cause) and breast cancer in women (Table A in S1 Supporting Information). In addition, we included infertility, non-alcoholic fatty liver disease (NAFLD) and chronic liver disease (CLD) as they have previously been linked to obesity and represent important and increasing burdens of disease (25–31). For T2D and T1D, we drew case definitions from a validated algorithm for prevalent T2D and T1D (using “probable” and “possible” cases) and those the algorithm denoted as “diabetes unlikely” were used as controls (32). For CAD, we used the same case and control definitions as a large GWAS (33). Case and control criteria for the other disease outcomes were defined using self-report data, data from an interview with a trained nurse, and hospital health outcome codes in discussion between two licensed medical practitioners (Table A in S1 Supporting Information). For CAD, acute renal failure, chronic renal failure, stroke of any cause, ischemic stroke and hemorrhagic stroke, exclusions for certain codes were also made in the control groups after defining the case groups.

To assess potential mediation, we also investigated associations between the obesity traits and the potential cardiometabolic risk factors systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose (FG), fasting insulin (FI), and smoking status.

Baseline measurements were used for all continuous traits, including BMI, WHR, WHRadjBMI, SBP and DBP. For SBP and DBP, the mean of the up to two baseline measurements were used. Fifteen mmHg to SBP and 10 mmHg to DBP were added if blood pressure lowering medications were used (defined as self-reported use of such in data-fields 6153 and 6177), as in previous blood pressure GWASs and as suggested in simulation studies (34,35). These anthropometric and blood pressure measurements were then standardized by rank inverse normal transformation of the residuals after regression of the trait on baseline age, age², assessment centre, and, if applicable, sex. This was done separately in the men and women only analyses, but jointly in the combined analyses, after any sample quality exclusions (S1 Supporting Information). WHRadjBMI was generated in a similar manner, but with adjustment for BMI as well, as in the original GWAS (15).

Sex-specific summary-level data for plasma FG (in mmol/L, untransformed, corrected to plasma levels using a correction factor of 1.13 if measured in whole blood in the original GWAS) and serum FI (in pmol/L, ln-transformed) were kindly provided by the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) investigators and can be downloaded from <https://www.magicinvestigators.org/downloads/> (36). SNPs in chromosome:position format were converted to rsIDs using the file All_20150605.vcf.gz from the National Center for Biotechnology Information (NCBI) (37) (available at ftp://ftp.ncbi.nih.gov/snp/organisms/archive/human_9606_b144_GRCh37p13/VCF/). All SNPs were then updated to dbSNP build 151 using the file RsMergeArch.bcp.gz, also from the NCBI (37) (available at ftp://ftp.ncbi.nlm.nih.gov/snp/organisms/human_9606/database/organism_data/).

Smoking status was defined as self-report of being a current or previous smoker or having smoked or currently smoking (most days or occasionally; any code 1 or 2 in any of the data fields 1239, 1249, and 20116).

Statistical analyses

The GRSs were first assessed if they were robustly associated with their respective obesity traits by computing trait variance explained and the F-statistics (S1 Supporting Information, Table B in S1 Supporting Information).

We explored the associations of sex-specific GRSs with outcomes in the UK Biobank (21). For disease outcomes and smoking status, logistic regression was used while for continuous traits (including evaluation of the GRSs in their respective obesity traits and the blood pressure traits) linear regression was used. Associations of sex-specific GRSs with outcome traits that surpassed our P-value thresholds were taken forward for MR to more formally quantify the effect of the obesity trait on the outcome.

Individual-level MR was performed using the Wald method, with the instrumental variable estimate being the ratio between the outcome and risk factor regressed separately on each GRS (38). Standard errors were adjusted to take the uncertainty in both regressions into account by using the first two

terms of the delta method (39–41). MR regressions of the risk factors on the GRSs was performed in controls only for the binary outcomes.

Adjustments were made for baseline age, age², array type, assessment centre, 10 principal components, and sex if applicable, for all traits when in clinical units, and array and 10 principal components if rank inverse normal transformed (where adjustment for age, age², assessment centre, and if applicable sex had already been performed in the rank inverse normal transformation of the residuals).

Two-sample MR was performed for the effect of the obesity traits on FG and FI, including the inverse-variance weighted (IVW), MR-Egger, and weighted median methods (42–45).

For the obesity trait-risk factor analyses, the P-value threshold was set at <0.003 (=0.05/15) for the regressions and the MRs, for the total of 15 obesity trait-risk factor combinations investigated in the study. We conducted MRs for all obesity traits with smoking status for completeness, since we performed analyses adjusting for smoking status as a sensitivity analysis. We also performed summary-level MRs for the potential risk factors FG and FI directly, as we only had summary-level data for these traits. For the obesity trait-disease analyses, the P-value thresholds for both the regressions and the MRs were set at <0.001 (=0.05/51) for 51 obesity trait-disease combinations investigated in the study. If a combined-sexes regression analysis identified evidence against the null hypothesis it was taken forward for MR; if a regression analysis identified evidence against the null hypothesis in either men or women, MR was performed in both sexes so sexual heterogeneity could be assessed. Sexual heterogeneity between male and female estimates from the linear and logistic regressions and the MRs was assessed using P-values from Cochran's Q test (46). To facilitate comparisons between the obesity traits and sex-strata, estimates were computed per 1 standard deviation (SD) higher obesity trait.

Sensitivity analyses

We performed several sensitivity analyses to ascertain robustness; we performed (a) analyses adjusting for smoking status and (b) analyses restricted to those of genetically confirmed British ancestry only

(S1 Supporting Information). We also (c) evaluated the robustness of the MR findings by comparing different weighting strategies, including use of unweighted and externally weighted (using weights from the GIANT 2015 studies (22,23)) GRSs, and (d) investigated for pleiotropy and performed more pleiotropy-robust sensitivity analyses (44,45) (S1 Supporting Information). We also (e) performed logistic regressions using the same number of cases and controls in men and women for the disease outcomes and (f) conducted analyses using stricter T2D and T1D case definitions (S1 Supporting Information).

Software

The genotype data was handled PLINK v2.00aLM and PLINK v1.90b3 (47) (S1 Supporting Information). Further data handling was performed in Python 3.5.2 (48) using the packages “pandas” (49) and “numpy” (50), R version 3.4.3 (51) and the package “dplyr” (52), bash version 4.1.2(2) (53) and awk (54). Statistical analyses and plots were performed using R version 3.4.3 (51) and packages “ggplot2” (55), “mada” (56), “dplyr” (52), “gridExtra” (57), “lattice” (58), “grid” (51), “grDevices” (51), “ggpubr” (59), and “MendelianRandomization” (42).

Results

Evaluation of genetic risk scores

The GRSs included 565 SNPs for BMI, 324 for WHR and 338 for WHRadjBMI. Trait variance explained varied between 2.5-7.1% and the F-statistic between 4,941-26,311, depending on trait and sex-stratum (Table B in S1 Supporting Information). After having assessed the associations between GRSs and risk factors and disease outcomes using regression analyses, associations that surpassed correction for multiple testing were taken forward for MR (Table C-E and Fig C in S1 Supporting Information).

Several instruments were positively associated with smoking status and with higher estimates in men than in women for both BMI as well as WHR (BMI: $P_{\text{het}}=4.7 \times 10^{-4}$; WHR: $P_{\text{het}}=1.3 \times 10^{-13}$; WHRadjBMI $P_{\text{het}}=0.007$) (Table D in S1 Supporting Information). We therefore ran the individual-level MRs adjusting for smoking status to assess potential mediation.

Mendelian randomization of obesity with disease outcomes: all individuals

Obesity traits were causally implicated with diseases that represent the major causes of death (Fig 2 and 3). All measures of obesity were strongly causally related to risk of CAD (odds ratio (OR) ranging from 1.39 for WHRadjBMI to 1.73 for WHR in the combined analyses per 1-SD higher obesity trait). For stroke, both BMI and WHR conferred higher risk (ORs 1.41 and 1.33, respectively). Strong effects were seen for all obesity traits with T2D (OR range 2.13 to 3.64) and BMI also associated with risk of T1D (OR 1.68). Obesity traits increased the risk of kidney disease, including both acute (ORs 1.55 for WHR and 1.80 for BMI) and chronic (ORs 1.72 for WHR and 1.79 for BMI) renal failure. Measures of obesity also causally impacted on risks of COPD (OR 1.68 for BMI and 1.45 for WHR) and lung cancer (BMI OR 1.34). Adjusting for smoking status resulted in reduced magnitudes of effects for COPD and lung cancer traits, suggesting potential mediation (Table F in S1 Supporting Information). In addition to these endpoints, strong effects were seen for risk of NAFLD (OR range 1.61-2.85) and CLD (ORs 1.62 for BMI and 1.83 for WHR).




Fig 2. Causal effects of obesity traits on disease outcomes, overall and stratified by sex.

The obesity trait-disease combinations brought forward for Mendelian randomization, with estimates given in odds ratio (95% CI) per 1-SD higher obesity trait. Filled diamonds indicate that the P-value for the obesity trait

to disease endpoint surpasses our threshold for multiple testing; empty diamonds indicate that the P-value does not surpass this threshold (Bonferroni-adjusted P-value-threshold set at <0.001 ($=0.05/51$) for 51 obesity trait-disease outcome combinations in the study). * denotes that the P-value for heterogeneity (from Cochran's Q test) surpasses our threshold for multiple testing; P_{het} -threshold set at <0.001 ($=0.05/48$) for 48 male-female comparisons in the study (fewer since breast cancer analyses were performed in women only). ♦, combined-sexes estimates; ♦, male estimates; ♦, female estimates; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; NAFLD, non-alcoholic fatty liver disease; SD standard deviation; WHR, waist-hip-ratio; WHRadjBMI, waist-hip-ratio adjusted for body mass index.



387

388 **Fig 3. Overview of the sex-specific effect magnitudes and strengths of association of obesity traits on leading causes of death.**

389 Leading causes of death defined as non-communicable diseases on the WHO top 10 lists of causes of death, globally and in high-income countries, with additional separate

analyses for subclasses of stroke, diabetes, and renal disease. No obesity trait (BMI, WHR, or WHRadjBMI) genetic risk score associated with dementia, colorectal cancer, breast cancer (investigated in women only) or hemorrhagic stroke – these are not shown on the plot. (A) Total number of deaths globally, in 1,000 deaths, as estimated by the WHO for 2016 (60), stratified by sex. For diabetes, estimates for annual number of deaths are for type 1 and type 2 diabetes combined. (B) Obesity trait-disease combinations taken forward for Mendelian randomization showed with circles. Mendelian randomization associations with P-values surpassing our threshold in yellow to red fill depending on P-value ($-\log_{10}$ P-value), white fill indicates a P-value not surpassing our threshold. The size of the circles corresponds to the magnitude of the odds ratio estimate for the Mendelian randomization estimate. Estimates and P-values from the MR analyses of the obesity traits with the disease outcomes using the sex-specific estimates approach. BMI, body mass index; P, P-value; WHR, waist-hip-ratio; WHRadjBMI, waist-hip-ratio adjusted for body mass index; WHO, World Health Organization.

Sensitivity analyses, including restricting analyses to those of genetically confirmed British ancestry only, use of different weighting strategies, analyses using more pleiotropy-robust methods, using the same number of cases and controls in men and women, and use of more stringent diabetes case definitions supported the main findings (S1 Supporting Information, Tables G,H and Fig D-F in S1 Supporting Information).

Mendelian randomization of obesity with disease outcomes: sex-stratified analyses

Five obesity trait-disease associations differed between women and men (Fig 2). The risk of T2D from 1-SD higher BMI was higher in women (OR 3.81; 95% CI 3.42-4.25, $P=8.9 \times 10^{-130}$) than men (OR 2.78; 95% CI 2.57-3.02, $P=1.0 \times 10^{-133}$), with strong evidence for sexual heterogeneity ($P_{\text{het}}=5.1 \times 10^{-6}$, P_{het} -threshold set at <0.001 ($=0.05/48$) for 48 male-female disease estimate comparisons, since breast cancer was investigated in women only). This sexual heterogeneity could also be observed in sensitivity analyses where the number of cases in women and men was similar ($P_{\text{het}}=4.4 \times 10^{-5}$) (Table H in S1 Supporting Information).

WHR increased risk of COPD to a greater extent in men (OR 1.87; 95% CI 1.61-2.17, $P=1.2 \times 10^{-16}$) than in women (OR 1.22; 95% CI 1.10-1.36, $P=2.0 \times 10^{-4}$, $P_{\text{het}}=5.5 \times 10^{-6}$), per 1-SD higher WHR. While the association of WHR with smoking was greater in men than in women (Table I in S1 Supporting Information) and estimates of WHR with COPD for both men and women attenuated after adjustment for smoking status, the association of WHR and COPD remained higher in men after adjusting for smoking ($P_{\text{het}}=1.2 \times 10^{-4}$; Table F in S1 Supporting Information).

There was also evidence of WHR leading to a higher risk on renal failure in men than in women. Men had a higher risk of chronic renal failure per 1-SD higher WHR, with the risk in men being OR 2.32

(95% CI 1.81-2.98, $P=4.4 \times 10^{-11}$) and in women OR 1.25 (95% CI 1.03-1.52, $P=0.02$, $P_{\text{het}}=1.3 \times 10^{-4}$), with similar sex differences seen for WHRadjBMI. Men also had a higher risk of acute renal failure (men: OR 1.88; 95% CI 1.49-2.36, $P=8.2 \times 10^{-8}$; women: OR 1.23; 95% CI 1.00-1.53, $P=0.05$, per 1-SD higher WHR, $P_{\text{het}}=0.009$), although the P_{het} -value did not pass our P_{het} -threshold.

Sensitivity analyses using different GRS weighting strategies strongly supported sex-differences in the effect of BMI on T2D and WHR on chronic renal failure and COPD, but only weakly supported a sex-difference in the effect of WHR on renal failure of any cause (S1 Supporting Information, Fig D,E in S1 Supporting Information).

Potential mechanisms

To identify potential mediators, we assessed the relationship of obesity traits with blood pressure (SBP, DBP), glycemic traits (FG, FI), and smoking status (Tables I-M in S1 Supporting Information). All obesity traits causally impacted risk on SBP, DBP, FG and FI. The increase in DBP arising from elevated BMI was greater in women than men ($P_{\text{het}}=3.5 \times 10^{-5}$, P_{het} -threshold set at <0.003 ($=0.05/15$) for 15 obesity trait-risk factor combinations). BMI and WHR both associated with higher risk of being a smoker, with the magnitudes of effect being larger in men than women (BMI $P_{\text{het}}=0.002$; WHR $P_{\text{het}}=3.7 \times 10^{-14}$). WHRadjBMI was only associated with smoking status in men.

Discussion

Our study demonstrates that obesity is causally implicated in the etiology of two thirds of the leading causes of death from non-communicable diseases (globally and in high-income countries) (24). Furthermore, we identify that for some diseases, obesity conveys altered magnitudes of risk in men and women. Such sexual dimorphism could be observed in the effects of BMI on T2D and waist-related traits on COPD and renal failure. These findings have potential implications for public health policy.

Obesity traits were causally related to higher risk of T2D, in alignment with previous studies (7–12,20,61). We could not detect a sex difference in risk of T2D from higher WHR or WHRadjBMI. Even though some observational studies have suggested that WHR may be a stronger predictor of T2D

risk in women than in men (19,20), studies investigating the effect on T2D risk from genetic predisposition to higher WHRadjBMI have not found evidence of sexual heterogeneity (7,10,12). In contrast, we found that BMI conferred a higher T2D risk in women than in men. Whereas men tend to be diagnosed with T2D at lower BMI than women (62), there may be a stronger association between increase of BMI and T2D risk in women than in men (16,19,61,63–66). Whether this reflects a stronger causal effect of BMI on T2D risk in women has hitherto been unknown. We found no evidence for sexual heterogeneity of the causal effect of BMI on potential glycaemic trait risk mediators (FG and FI). There have been indications of higher BMI being observationally associated with lower insulin sensitivity in men than in women, but this observed sex-difference may not reflect a causal pathway or we are not capturing it by our glycaemic measurements (67–69). We also found evidence of BMI causally increasing risk of T1D. Previous observational (70) and MR (71) studies have implicated childhood BMI in risk of T1D. As SNPs associated with adult BMI have also been found to affect childhood BMI (71,72), our results may well reflect the consequences of childhood BMI on T1D rather than adult BMI. The results were robust to use of a stricter T1D case definition, minimizing risk of erroneous finding due to misclassification of diabetes type.

Higher BMI, WHR and WHRadjBMI increased risk of CAD in both sexes, as shown previously (4,7–9,11,12,16,18). Our obesity trait-CAD analyses did not show evidence for sexual heterogeneity. Observational studies have indicated that waist-related traits may be more strongly associated with cardiovascular disease in women and men, but have not been conclusive (16,18,73). However, a recent study (12) investigated the effect of higher WHRadjBMI, lower gluteofemoral fat distribution, and higher abdominal fat distribution, proxied by genetic variants, on CAD and T2D risk and found no evidence that relationships differed between men and women, similar to our findings. BMI and WHR have previously been observationally associated with risk of stroke (74–76) and a previous MR study found a causal effect of BMI on ischemic stroke (77). However, some studies have found WHR to be an epidemiological risk factor for stroke in men only (74,75). Our results confirm BMI as a causal risk factor for overall stroke in both men and women. In women, the effects of WHR were directionally

consistent with harm, but the estimates were imprecise, probably reflecting insufficient power in the sex-stratified analysis.

Our results also indicate that higher BMI and WHR increase risk of COPD and higher BMI the risk of lung cancer; a likely common mechanism is through smoking. BMI has previously been implicated in COPD, but is not an established epidemiological nor causative risk factor (8,78–80). Obesity may directly contribute to COPD as its diagnosis is partly based on spirometry values, and obesity is associated with lower lung function (80,81). Higher BMI also increased risk of lung cancer in our study, similar to a previous MR study (82). Observational studies tend to identify associations between smoking and lower body weight, but whereas smoking lowers body weight, higher BMI is associated with increased smoking (82–85). We found associations between particularly BMI and WHR with smoking propensity. To assess mediation, we therefore conducted analyses adjusting for smoking status. This attenuated the associations between the obesity markers and risk of COPD and lung cancer, suggesting that smoking status may be on the causal pathway between obesity, COPD and lung cancer. This diminution does not discredit the validity of the MR analyses unadjusted for smoking provided that the obesity instruments only affect smoking propensity through altered obesity (86). Rather, they suggest that higher BMI impacts on disease beyond the immediate physiological effects of obesity: by altering human behavior (i.e. increased smoking, likely motivated as a weight loss strategy (87,88)) and this increased propensity to smoking has additional, far-reaching, deleterious effects on human health, as evidenced by the higher risks of serious lung disease. Higher WHR was associated with higher effects on both COPD and being a smoker in men than in women. Whereas the sex difference in the effect of WHR on COPD persisted after adjustment for smoking status, we cannot rule out that WHR has a higher effect on COPD in men than women through its effect on smoking propensity, but that our smoking phenotype does not fully capture the life-long effects of smoking in men and women.

Our results also provide further evidence for a role of obesity traits in both acute and chronic renal failure using an MR design — previous MR studies assessing these relationships have not been conclusive (7,8,89–91). Obesity may affect chronic renal disease through a number of mechanisms,

including structural changes in the kidney and through higher risks of mediating diseases, such as T2D and renal cell carcinoma (91–95). We found central fat distribution (as measured by WHR and WHRadjBMI) to have higher effects on chronic renal failure in men than in women, with evidence of sexual heterogeneity. The reason for this sex difference is unclear — a recent MR study found both BMI and WHR to increase risk of renal cell carcinoma but with no difference in risk between men and women (95).

Obesity traits associated with increased risk of NAFLD and CLD (important and emerging causes of chronic disease and mortality (27–30)), with the effect on CLD possibly mediated by NAFLD, since CLD may be caused by NAFLD (28). A previous MR study found BMI to increase hepatic triglyceride content (96). Our study confirms a role of both general obesity and central fat distribution in NAFLD and CLD using an MR design. This strengthens evidence of a causal effect and emphasizes the risk of increased CLD burden if the obesity prevalence continues to increase (1,27–30).

Strengths and limitations

Genetic instruments should only affect the outcome through the risk factor of interest and not through any confounders (97,98). We performed sensitivity analyses (MR-Egger, weighted-median based methods) more robust to such bias, which supported the main findings (44,45).

If instruments are weakly associated with their respective traits, it can introduce bias in MR studies (99). We therefore only used instruments strongly associated with their respective risk factor, and performed sensitivity analyses using a variety of SNP-selection and weighting approaches, including unweighted and externally weighted scores, which also supported the main results (41,99,100).

Recent studies have also indicated that there may be slight population stratification in both GIANT and UKBB, although such bias is likely to be minor (101,102). Our study was restricted to individuals of Europeans ancestry; limiting our analyses to those of British ancestry only yielded near-identical results. Associations between the obesity traits and outcomes may differ in other ancestries.

Finally, it is possible that our genetic instrument for WHRadjBMI might show features of collider bias whereby SNPs included in the GRS associate with both higher WHR and lower BMI leading to

potentially spurious findings (103). We note that a recent GWAS (15) evaluated the potential for collider bias in the WHRadjBMI GWAS and found limited evidence for such, although the GRS was associated with higher WHR and lower BMI. The directional consistency of associations between WHR and WHRadjBMI and disease endpoints in our analysis suggests that collider bias is unlikely to represent a major source of error in this study.

Conclusion

Global prevalence of obesity is increasing (1). Our results implicate major obesity traits (BMI, WHR, and WHRadjBMI) in the etiology of the leading causes of death globally, including CAD, stroke, type 2 and 1 diabetes, COPD, lung cancer and renal failure, as well as NAFLD and CLD. The risk increase from obesity traits differs between men and women for T2D, renal failure and COPD. This emphasizes the importance of improved preventative measures and treatment of obesity-related disorders and implies that women and men may experience different disease sequelae from obesity, with potential implications for provision of health services and health policy.

Acknowledgements

JCC is funded by the Oxford Medical Research Council Doctoral Training Partnership (Oxford MRC DTP) and the Nuffield Department of Clinical Medicine, University of Oxford. JB is supported by funding from the Rhodes Trust, Clarendon Fund and the Medical Sciences Doctoral Training Centre, University of Oxford. SLP has a Veni Fellowship (016.186.071; ZonMW) from the Dutch Organization for Scientific Research, Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO). MVH works in a unit that receives funding from the MRC and is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre, and has collaborated with Boehringer Ingelheim in research, and in accordance with the policy of the Clinical Trial Service Unit and Epidemiological Studies Unit (University of Oxford), did not accept any personal payment. CML is supported by the Li Ka Shing Foundation; WT-SSI/John Fell funds; the NIHR Biomedical Research Centre, Oxford; Widenlife; and NIH (5P50HD028138-27). TF, AM, RM report no conflicts of interest. We thank the UK Biobank (<http://www.ukbiobank.ac.uk/>; application 11867).

References

1. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med*. 2017 Jul 6;377(1):13–27.
2. Seidell JC, Oosterlee A, Thijssen MA, Burema J, Deurenberg P, Hautvast JG, et al. Assessment of intra-abdominal and subcutaneous abdominal fat: relation between anthropometry and computed tomography. *Am J Clin Nutr*. 1987 Jan;45(1):7–13.
3. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet*. 2009 Mar 28;373(9669):1083–96.
4. Taylor AE, Ebrahim S, Ben-Shlomo Y, Martin RM, Whincup PH, Yarnell JW, et al. Comparison of the associations of body mass index and measures of central adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: a study using data from 4 UK cohorts. *Am J Clin Nutr*. 2010 Mar 1;91(3):547–56.
5. WHO. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO consultation. Geneva: World Health Organization; 2000.
6. Davies NM, Holmes M V, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ*. 2018 Jul 12;362:k601.
7. Emdin CA, Khera A V, Natarajan P, Klarin D, Zekavat SM, Hsiao AJ, et al. Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. *JAMA*. 2017 Feb 14;317(6):626–34.
8. Millard LAC, Davies NM, Tilling K, Gaunt TR, Smith GD. Searching for the causal effects of BMI in over 300 000 individuals, using Mendelian randomization. *bioRxiv*. 2017 Dec 19;236182.
9. Lyall DM, Celis-Morales C, Ward J, Iliodromiti S, Anderson JJ, Gill JMR, et al. Association of Body Mass Index With Cardiometabolic Disease in the UK Biobank. *JAMA Cardiol*. 2017 Aug 1;2(8):882.
10. Huang T, Qi Q, Zheng Y, Ley SH, Manson JE, Hu FB, et al. Genetic Predisposition to Central Obesity and Risk of Type 2 Diabetes: Two Independent Cohort Studies. *Diabetes Care*. 2015 Jul;38(7):1306–11.
11. Dale CE, Fatemifar G, Palmer TM, White J, Prieto-Merino D, Zabaneh D, et al. Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus: A Mendelian Randomization Analysis. *Circulation*. 2017 Jun 13;135(24):2373–88.
12. Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J, et al. Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors. *JAMA*. 2018 Dec 25;320(24):2553.
13. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. *Lancet*. 2011 Feb 12;377(9765):557–67.
14. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet (London, England)*. 2014 Aug 30;384(9945):766–81.

15. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694,649 individuals of European ancestry. *Hum Mol Genet*. 2018 Sep 14;
16. Rost S, Freuer D, Peters A, Thorand B, Holle R, Linseisen J, et al. New indexes of body fat distribution and sex-specific risk of total and cause-specific mortality: a prospective cohort study. *BMC Public Health*. 2018 Dec 2;18(1):427.
17. Lind L, Ärnlov J, Lampa E. The Interplay Between Fat Mass and Fat Distribution as Determinants of the Metabolic Syndrome Is Sex-Dependent. *Metab Syndr Relat Disord*. 2017 Sep 1;15(7):337–43.
18. Dagenais GR, Yi Q, Mann JFE, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. *Am Heart J*. 2005 Jan 1;149(1):54–60.
19. Meisinger C, Döring A, Thorand B, Heier M, Löwel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg Cohort Study. *Am J Clin Nutr*. 2006 Dec 1;84(3):483–9.
20. Wannamethee SG, Papacosta O, Whincup PH, Carson C, Thomas MC, Lawlor DA, et al. Assessing prediction of diabetes in older adults using different adiposity measures: a 7 year prospective study in 6,923 older men and women. *Diabetologia*. 2010 May 10;53(5):890–8.
21. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv*. 2017 Jul 20;166298.
22. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015 Feb 12;518(7538):197–206.
23. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature*. 2015 Feb 12;518(7538):187–96.
24. World Health Organization. The top 10 causes of death [Internet]. 2018 [cited 2018 Jul 7]. Available from: <http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
25. Campbell JM, Lane M, Owens JA, Bakos HW. Paternal obesity negatively affects male fertility and assisted reproduction outcomes: a systematic review and meta-analysis. *Reprod Biomed Online*. 2015 Nov 1;31(5):593–604.
26. van der Steeg JW, Steures P, Eijkemans MJC, Habbema JDF, Hompes PGA, Burggraaff JM, et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. *Hum Reprod*. 2007 Dec 14;23(2):324–8.
27. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study. *Gastroenterology*. 2011 Jan 1;140(1):124–31.
28. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*. 2012 Jun 1;55(6):2005–23.
29. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther*. 2011 Aug 1;34(3):274–85.
30. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic

646 fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology*.
647 2018;67(1):123–33.

648 31. Macaluso M, Wright-Schnapp TJ, Chandra A, Johnson R, Satterwhite CL, Pulver A, et al. A
649 public health focus on infertility prevention, detection, and management. *Fertil Steril*. 2010 Jan
650 1;93(1):16.e1-16.e10.

651 32. Eastwood S V, Mathur R, Atkinson M, Brophy S, Sudlow C, Flaig R, et al. Algorithms for the
652 Capture and Adjudication of Prevalent and Incident Diabetes in UK Biobank. Herder C, editor.
653 *PLoS One*. 2016 Sep 15;11(9):e0162388.

654 33. Nelson CP, Goel A, Butterworth AS, Kanoni S, Webb TR, Marouli E, et al. Association
655 analyses based on false discovery rate implicate new loci for coronary artery disease. *Nat*
656 *Genet*. 2017 Jul 17;49(9):1385–91.

657 34. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for treatment effects in studies of
658 quantitative traits: antihypertensive therapy and systolic blood pressure. *Stat Med*. 2005 Oct
659 15;24(19):2911–35.

660 35. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB,
661 Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways
662 influence blood pressure and cardiovascular disease risk. *Nature*. 2011 Sep 11;478(7367):103–
663 9.

664 36. Lagou V, Mägi R, Hottenga J-J. Fasting glucose and insulin variability: sex-dimorphic genetic
665 effects and novel loci. *Prep*. 2018;

666 37. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI
667 database of genetic variation. *Nucleic Acids Res*. 2001 Jan 1;29(1):308–11.

668 38. Wald A. The Fitting of Straight Lines if Both Variables are Subject to Error. *Ann Math Stat*.
669 1940 Sep;11(3):284–300.

670 39. Bautista LE, Smeeth L, Hingorani AD, Casas JP. Estimation of Bias in Nongenetic
671 Observational Studies Using “Mendelian Triangulation.” *Ann Epidemiol*. 2006 Sep
672 1;16(9):675–80.

673 40. Thomas DC, Lawlor DA, Thompson JR. Re: Estimation of Bias in Nongenetic Observational
674 Studies Using “Mendelian Triangulation” by Bautista et al. *Ann Epidemiol*. 2007
675 Jul;17(7):511–3.

676 41. Burgess S, Thompson SG. *Mendelian Randomization - Methods for Using Genetic Variants in*
677 *Causal Estimation*. 1st ed. Boca Raton, FL, USA: CRC Press, Taylor & Francis Group,
678 Chapman and Hall; 2005. 6, 20, 45-52, 67, 124 p.

679 42. Yavorska OO, Burgess S. *MendelianRandomization*: an R package for performing Mendelian
680 randomization analyses using summarized data. *Int J Epidemiol*. 2017 Dec 1;46(6):1734–9.

681 43. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple
682 genetic variants using summarized data. *Genet Epidemiol*. 2013 Nov;37(7):658–65.

683 44. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
684 effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015 Apr
685 1;44(2):512–25.

686 45. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian
687 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet*
688 *Epidemiol*. 2016 May;40(4):304–14.

689 46. Cochran W. The combination of estimates from different experiments. *Biometrics*. 1954;10:
690 101-29.

- 691 47. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool
692 Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am J Hum*
693 *Genet.* 2007 Sep;81(3):559–75.
- 694 48. Python Software Fondation. Python, version 3.5.2 [Internet]. Available from:
695 <https://www.python.org/>
- 696 49. McKinney W. Data Structures for Statistical Computing in Python. *Proc 9th Python Sci Conf.*
697 2010;51–6.
- 698 50. Oliphant TE. A guide to NumPy. USA: Trelgol Publishing; 2006.
- 699 51. R Core Team. R: A language and environment for statistical computing. R Foundation for
700 Statistical Computing, Vienna, Austria [Internet]. 2017. Available from: [https://www.r-](https://www.r-project.org/)
701 [project.org/](https://www.r-project.org/)
- 702 52. Wickham H, Francois R, Henry L, Müller K. dplyr: A Grammar of Data Manipulation. R
703 package version 0.7.4. 2017;
- 704 53. Free Software Foundation. bash 4.1.2(2) [Internet]. 2007. Available from:
705 <https://www.gnu.org/software/bash/>
- 706 54. Free Software Foundation. GNU AWK 3.1.7 [Internet]. 1989. Available from:
707 <https://www.gnu.org/software/gawk/manual/gawk.html>
- 708 55. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag; 2009.
- 709 56. Doebler P. mada: Meta-Analysis of Diagnostic Accuracy. R package version 0.5.8. [Internet].
710 2017. Available from: <https://cran.r-project.org/package=mada%0A>
- 711 57. Auguie B. gridExtra: Miscellaneous Functions for “Grid” Graphics [Internet]. R package
712 version 2.3. 2017. Available from: <https://cran.r-project.org/package=gridExtra>
- 713 58. Sarkar D. Lattice: Multivariate Data Visualization with R. New York: Springer; 2008.
- 714 59. Kassambara A. ggpubr: “ggplot2” Based Publication Ready Plots. R package version 0.1.7.
715 2018.
- 716 60. World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by
717 Country and by Region, 2000-2016. Geneva; 2018.
- 718 61. Vazquez G, Duval S, Jacobs DR, Silventoinen K. Comparison of Body Mass Index, Waist
719 Circumference, and Waist/Hip Ratio in Predicting Incident Diabetes: A Meta-Analysis.
720 *Epidemiol Rev.* 2007 May 2;29(1):115–28.
- 721 62. Logue J, Walker JJ, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, et al. Do men develop
722 type 2 diabetes at lower body mass indices than women? *Diabetologia.* 2011 Dec
723 30;54(12):3003–6.
- 724 63. Bray GA. Medical Consequences of Obesity. *J Clin Endocrinol Metab.* 2004 Jun 1;89(6):2583–
725 9.
- 726 64. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology
727 and Complications of Type 2 Diabetes Mellitus. *Endocr Rev.* 2016;37(3):278–316.
- 728 65. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical
729 diabetes mellitus in women. *Ann Intern Med.* 1995 Apr 1;122(7):481–6.
- 730 66. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and
731 weight gain as risk factors for clinical diabetes in men. *Diabetes Care.* 1994 Sep;17(9):961–9.
- 732 67. Sierra-Johnson J, Johnson BD, Bailey KR, Turner ST. Relationships between insulin sensitivity

733 and measures of body fat in asymptomatic men and women. *Obes Res.* 2004 Dec;12(12):2070–
734 7.

735 68. Masharani U, Goldfine ID, Youngren JF. Influence of gender on the relationship between
736 insulin sensitivity, adiposity, and plasma lipids in lean nondiabetic subjects. *Metabolism.* 2009
737 Nov;58(11):1602–8.

738 69. Quon MJ. Limitations of the Fasting Glucose to Insulin Ratio as an Index of Insulin Sensitivity.
739 *J Clin Endocrinol Metab.* 2001 Oct 1;86(10):4615–7.

740 70. Verbeeten KC, Elks CE, Daneman D, Ong KK. Association between childhood obesity and
741 subsequent Type 1 diabetes: a systematic review and meta-analysis. *Diabet Med.* 2011 Jan
742 1;28(1):10–8.

743 71. Censin JC, Nowak C, Cooper N, Bergsten P, Todd JA, Fall T. Childhood adiposity and risk of
744 type 1 diabetes: A Mendelian randomization study. *Langenberg C, editor. PLoS Med.* 2017
745 Aug 1;14(8):e1002362.

746 72. Felix JF, Bradfield JP, Monnereau C, van der Valk RJP, Stergiakouli E, Chesi A, et al.
747 Genome-wide association analysis identifies three new susceptibility loci for childhood body
748 mass index. *Hum Mol Genet.* 2016 Jan 15;25(2):389–403.

749 73. Li C, Engström G, Hedblad B, Calling S, Berglund G, Janzon L. Sex differences in the
750 relationships between BMI, WHR and incidence of cardiovascular disease: a population-based
751 cohort study. *Int J Obes.* 2006 Dec 11;30(12):1775–81.

752 74. Hu G, Tuomilehto J, Silventoinen K, Sarti C, Männistö S, Jousilahti P. Body Mass Index,
753 Waist Circumference, and Waist-Hip Ratio on the Risk of Total and Type-Specific Stroke.
754 *Arch Intern Med.* 2007 Jul 9;167(13):1420.

755 75. Abete I, Arriola L, Etxezarreta N, Mozo I, Moreno-Iribas C, Amiano P, et al. Association
756 between different obesity measures and the risk of stroke in the EPIC Spanish cohort. *Eur J*
757 *Nutr.* 2015 Apr 6;54(3):365–75.

758 76. The Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI
759 Mediated Effects). Metabolic mediators of the effects of body-mass index, overweight, and
760 obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with
761 1·8 million participants. *Lancet.* 2014 Mar 15;383(9921):970–83.

762 77. Hagg S, Fall T, Ploner A, Magi R, Fischer K, Draisma HH, et al. Adiposity as a cause of
763 cardiovascular disease: a Mendelian randomization study. *Int J Epidemiol.* 2015 Apr
764 1;44(2):578–86.

765 78. Vozoris NT, O'Donnell DE. Prevalence, risk factors, activity limitation and health care
766 utilization of an obese, population-based sample with chronic obstructive pulmonary disease.
767 *Can Respir J.* 2012;19(3):e18-24.

768 79. Hanson C, Rutten EP, Wouters EFM, Rennard S. Influence of diet and obesity on COPD
769 development and outcomes. *Int J Chron Obstruct Pulmon Dis.* 2014;9:723–33.

770 80. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global Strategy for
771 the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. *Am J*
772 *Respir Crit Care Med.* 2013 Feb 15;187(4):347–65.

773 81. Bedell GN, Wilson WR, Seeböhm PM. Pulmonary function in obese persons. *J Clin Invest.*
774 1958 Jul;37(7):1049–60.

775 82. Carreras-Torres R, Johansson M, Haycock PC, Wade KH, Relton CL, Martin RM, et al.
776 Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian
777 randomization study. *Hu C, editor. PLoS One.* 2017 Jun 8;12(6):e0177875.

- 778 83. Morris RW, Taylor AE, Fluharty ME, Bjørngaard JH, Åsvold BO, Elvestad Gabrielsen M, et
779 al. Heavier smoking may lead to a relative increase in waist circumference: evidence for a
780 causal relationship from a Mendelian randomisation meta-analysis. The CARTA consortium.
781 *BMJ Open*. 2015 Aug 11;5(8):e008808.
- 782 84. Audrain-McGovern J, Benowitz NL. Cigarette smoking, nicotine, and body weight. *Clin*
783 *Pharmacol Ther*. 2011 Jul;90(1):164–8.
- 784 85. Rásky E, Stronegger WJ, Freidl W. The relationship between body weight and patterns of
785 smoking in women and men. *Int J Epidemiol*. 1996 Dec;25(6):1208–12.
- 786 86. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG, EPIC- InterAct
787 Consortium. Using published data in Mendelian randomization: a blueprint for efficient
788 identification of causal risk factors. *Eur J Epidemiol*. 2015 Jul 15;30(7):543–52.
- 789 87. Chioloro A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat
790 distribution, and insulin resistance. *Am J Clin Nutr*. 2008 Apr 1;87(4):801–9.
- 791 88. Fulkerson JA, French SA. Cigarette smoking for weight loss or control among adolescents:
792 gender and racial/ethnic differences. *J Adolesc Health*. 2003 Apr;32(4):306–13.
- 793 89. Geng T, Smith CE, Li C, Huang T. Childhood BMI and Adult Type 2 Diabetes, Coronary
794 Artery Diseases, Chronic Kidney Disease, and Cardiometabolic Traits: A Mendelian
795 Randomization Analysis. *Diabetes Care*. 2018 May 1;41(5):1089–96.
- 796 90. Todd JN, Dahlström EH, Salem RM, Sandholm N, Forsblom C, FinnDiane Study Group the
797 FS, et al. Genetic Evidence for a Causal Role of Obesity in Diabetic Kidney Disease. *Diabetes*.
798 2015 Dec;64(12):4238–46.
- 799 91. van Zuydam NR, Ahlqvist E, Sandholm N, Deshmukh H, Rayner NW, Abdalla M, et al. A
800 Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2
801 Diabetes. *Diabetes*. 2018 Jul 1;67(7):1414–27.
- 802 92. Tsuboi N, Utsunomiya Y, Kanzaki G, Koike K, Ikegami M, Kawamura T, et al. Low
803 glomerular density with glomerulomegaly in obesity-related glomerulopathy. *Clin J Am Soc*
804 *Nephrol*. 2012 May 1;7(5):735–41.
- 805 93. Kovesdy CP, Furth SL, Zoccali C, World Kidney Day Steering Committee on behalf of the
806 WKDS. Obesity and Kidney Disease: Hidden Consequences of the Epidemic. *Can J kidney*
807 *Heal Dis*. 2017;4:2054358117698669.
- 808 94. Wang F, Xu Y. Body mass index and risk of renal cell cancer: a dose-response meta-analysis
809 of published cohort studies. *Int J cancer*. 2014 Oct 1;135(7):1673–86.
- 810 95. Johansson M, Carreras-Torres R, Scelo G, Purdue MP, Mariosa D, Muller DC, et al. The
811 influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian
812 randomization study. Minelli C, editor. *PLOS Med*. 2019 Jan 3;16(1):e1002724.
- 813 96. Stender S, Kozlitina J, Nordestgaard BG, Tybjaerg-Hansen A, Hobbs HH, Cohen JC. Adiposity
814 amplifies the genetic risk of fatty liver disease conferred by multiple loci. *Nat Genet*. 2017
815 Jun;49(6):842–7.
- 816 97. Greenland S. An introduction to instrumental variables for epidemiologists. *Int J Epidemiol*.
817 2000 Aug;29(4):722–9.
- 818 98. Martens EP, Pestman WR, de Boer A, Belitser S V, Klungel OH. Instrumental variables:
819 application and limitations. *Epidemiology*. 2006 May;17(3):260–7.
- 820 99. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample
821 Mendelian randomization. *Genet Epidemiol*. 2016 Nov;40(7):597–608.

100. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian randomization. *Int J Epidemiol*. 2013 Aug;42(4):1134–44.
101. Berg JJ, Harpak A, Sinnott-Armstrong N, Joergensen AM, Mostafavi H, Field Y, et al. Reduced signal for polygenic adaptation of height in UK Biobank. *bioRxiv*. 2018 Jun 27;354951.
102. Haworth S, Mitchell R, Corbin L, Wade KH, Dudding T, Budu-Aggrey A, et al. Common genetic variants and health outcomes appear geographically structured in the UK Biobank sample: Old concerns returning and their implications. *bioRxiv*. 2018 Apr 11;294876.
103. Davey Smith G, Paternoster L, Relton C. When Will Mendelian Randomization Become Relevant for Clinical Practice and Public Health? *JAMA*. 2017 Feb 14;317(6):589.

855 **Supporting Information**

856 **S1 Supporting Information.**